HRP20160058T1 - Postupci smanjenja razina eozinofila - Google Patents
Postupci smanjenja razina eozinofila Download PDFInfo
- Publication number
- HRP20160058T1 HRP20160058T1 HRP20160058TT HRP20160058T HRP20160058T1 HR P20160058 T1 HRP20160058 T1 HR P20160058T1 HR P20160058T T HRP20160058T T HR P20160058TT HR P20160058 T HRP20160058 T HR P20160058T HR P20160058 T1 HRP20160058 T1 HR P20160058T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- eosinophils
- use according
- reduction
- administration
- Prior art date
Links
- 210000003979 eosinophil Anatomy 0.000 title claims 18
- 108040006859 interleukin-5 receptor activity proteins Proteins 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gastroenterology & Hepatology (AREA)
Claims (12)
1. Monoklonsko, humanizirano IgG1 protutijelo koje veže IL-5R za upotrebu za smanjenje broja eozinofila kod subjekta koji je čovjek putem parenteralnog davanja navedenog protutijela navedenom subjektu u dozi od između 0.01 do 0.25 mg/kg i naznačeno time da navedeno protutijelo sadrži sekvencu aminokiseline iz SEQ ID NO: 1 i 3 i imunoglobulinsko Fc područje ne sadrži fukozu.
2. Protutijelo za upotrebu prema zahtjevu 1, naznačeno time da se navedeno protutijelo specifično veže na lanac IL-5R α.
3. Protutijelo za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačeno time da se smanjenje eozinofila odvija unutar prvih 48 sati od davanja.
4. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 3, naznačeno time da je smanjenje eozinofila reverzibilno.
5. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 4, naznačeno time da se brojevi eozinofila smanjuju na razinu koja je manja od 50 eozinofila / mm3.
6. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 5, naznačeno time da postoji smanjenje apsolutnog broja eozinofila nakon davanja od najmanje oko 25, najmanje oko 50, najmanje oko 75, najmanje oko 100, najmanje oko 125, najmanje oko 150, najmanje oko 175, najmanje oko 200, najmanje oko 225, najmanje oko 250, najmanje oko 275, najmanje oko 300, najmanje oko 325, najmanje oko 350, najmanje oko 375, najmanje oko 400, najmanje oko 425, najmanje oko 450, najmanje oko 475, ili najmanje oko 500 eozinofila / mm3.
7. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 6, naznačeno time da postoji smanjenje apsolutnog broja eozinofila nakon davanja od između i uključujući oko 50 do oko 500 eozinofila / mm3.
8. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 7, naznačeno time da je apsolutni broj eozinofila nakon davanja manji od oko 100, manji od oko 75, manji od oko 50, ili manji od oko 25 eozinofila / mm3.
9. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 8, naznačeno time da je apsolutni broj eozinofila kod subjekta prije davanja između oko 50 i oko 500 eozinofila / mm3.
10. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 9, naznačeno time da navedeni subjekt ima apsolutni broj eozinofila prije davanja oko 25, oko 50, oko 75, oko 100, oko 125, oko 150, oko 175, oko 200, oko 225, oko 250, oko 275, oko 300, oko 325, oko 350, oko 375, oko 400, oko 450, oko 475, ili oko 500 eozinofila / mm3.
11. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 10, naznačeno time da navedeno smanjenje eozinofila dovodi do smanjenja simptoma astme.
12. Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 10, naznačeno time da navedeno smanjenje eozinofila dovodi do ublažavanja simptoma KOPB.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92442207P | 2007-05-14 | 2007-05-14 | |
| US92483207P | 2007-06-01 | 2007-06-01 | |
| US93500507P | 2007-07-20 | 2007-07-20 | |
| US6461208P | 2008-03-14 | 2008-03-14 | |
| PCT/US2008/006156 WO2008143878A1 (en) | 2007-05-14 | 2008-05-14 | Methods of reducing eosinophil levels |
| EP08779619.9A EP2068927B1 (en) | 2007-05-14 | 2008-05-14 | Methods of reducing eosinophil levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160058T1 true HRP20160058T1 (hr) | 2016-04-22 |
Family
ID=40122040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160058TT HRP20160058T1 (hr) | 2007-05-14 | 2016-01-19 | Postupci smanjenja razina eozinofila |
| HRP20180611TT HRP20180611T1 (hr) | 2007-05-14 | 2018-04-17 | Postupci smanjenja razina bazofila |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180611TT HRP20180611T1 (hr) | 2007-05-14 | 2018-04-17 | Postupci smanjenja razina bazofila |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20100291073A1 (hr) |
| EP (2) | EP2068927B1 (hr) |
| JP (6) | JP2010527356A (hr) |
| KR (3) | KR101827179B1 (hr) |
| CN (2) | CN103223167B (hr) |
| AU (3) | AU2008255027B2 (hr) |
| BR (1) | BRPI0811526A2 (hr) |
| CA (2) | CA2685222C (hr) |
| CY (2) | CY1117594T1 (hr) |
| DK (2) | DK2068927T3 (hr) |
| ES (2) | ES2558689T3 (hr) |
| HK (3) | HK1132658A1 (hr) |
| HR (2) | HRP20160058T1 (hr) |
| HU (2) | HUE036885T2 (hr) |
| IL (2) | IL202102A (hr) |
| LT (1) | LT3072525T (hr) |
| MX (3) | MX2009012341A (hr) |
| NO (1) | NO3072525T3 (hr) |
| NZ (2) | NZ741494A (hr) |
| PL (2) | PL3072525T3 (hr) |
| PT (2) | PT3072525T (hr) |
| RU (2) | RU2519227C2 (hr) |
| SG (2) | SG10201503254TA (hr) |
| SI (2) | SI2068927T1 (hr) |
| WO (1) | WO2008143878A1 (hr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101715443A (zh) | 2007-03-14 | 2010-05-26 | 诺普神经科学股份有限公司 | 手性纯化的取代的苯并噻唑二胺的合成 |
| RU2519227C2 (ru) * | 2007-05-14 | 2014-06-10 | Медиммун, Ллк | Способы снижения числа эозинофилов |
| WO2010022140A1 (en) | 2008-08-19 | 2010-02-25 | Knopp Neurosciences, Inc. | Compositions and methods of using (r)-pramipexole |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| BR112013007862A2 (pt) | 2010-10-01 | 2019-09-24 | Moderna Therapeutics Inc | ácidos nucleicos manipulados e métodos de uso dos mesmos. |
| US20130052190A1 (en) * | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| EP2710370A4 (en) * | 2011-05-18 | 2015-01-07 | Medimmune Llc | METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| CN104039352A (zh) * | 2011-11-01 | 2014-09-10 | 米迪缪尼有限公司 | 用于降低哮喘急性恶化的频率和严重性的方法 |
| US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| JP6329717B2 (ja) | 2013-07-12 | 2018-05-23 | ノップ バイオサイエンシーズ エルエルシー | 高好酸球値および／または高好塩基球値の治療 |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| RS61565B1 (sr) * | 2013-08-12 | 2021-04-29 | Astrazeneca Ab | Postupci za povećanje forsiranog ekspiratornog volumena kod astmatičara korišćenjem benralizumaba |
| JP6746495B2 (ja) * | 2013-08-12 | 2020-08-26 | アストラゼネカ アクチボラグ | ベンラリツマブを使用して喘息の増悪率を低減する方法 |
| US9441047B2 (en) * | 2013-08-12 | 2016-09-13 | Astrazeneca Ab | Methods for improving asthma symptoms using benralizumab |
| AU2014306683B2 (en) | 2013-08-13 | 2017-10-12 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
| HUE055850T2 (hu) | 2013-08-13 | 2022-01-28 | Knopp Biosciences Llc | Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| RU2706729C2 (ru) * | 2013-10-15 | 2019-11-20 | Астразенека Аб | Способы лечения хронической обструктивной болезни легких с использованием бенрализумаба |
| CN105611938A (zh) | 2013-10-24 | 2016-05-25 | 免疫医疗有限责任公司 | 稳定的水性抗体配制品 |
| RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| CN113908269A (zh) * | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| AU2016272399B2 (en) * | 2015-06-01 | 2021-09-09 | Kyowa Kirin Co., Ltd. | Therapeutic agent and therapeutic method for pulmonary hypertension |
| AU2016349113A1 (en) | 2015-11-04 | 2018-06-07 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业（上海）股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
| CN112041338A (zh) * | 2017-12-29 | 2020-12-04 | 康奈尔大学 | 嗜酸性粒细胞病症的基因疗法 |
| JP2021535100A (ja) | 2018-08-24 | 2021-12-16 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | Ｍ２マクロファージ極性化を調節する方法及び治療におけるその使用 |
| TW202110479A (zh) | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| TW202214692A (zh) | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
| CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业（上海）股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
| KR102697770B1 (ko) * | 2020-09-14 | 2024-08-23 | 아주대학교산학협력단 | 인간 IL-5Rα에 결합하는 항체 및 이의 용도 |
| CN116887860A (zh) | 2020-12-17 | 2023-10-13 | 阿斯利康(瑞典)有限公司 | 抗il5r抗体配制品 |
| EP4405383A1 (en) * | 2021-09-22 | 2024-07-31 | Sonoma Biotherapeutics, Inc. | Il5ra cell surface markers |
| CN115671140B (zh) * | 2022-10-31 | 2024-03-22 | 华中科技大学同济医学院附属同济医院 | 丙酸痤疮杆菌在制备治疗鼻息肉的药品中的应用 |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633187A (en) | 1898-12-20 | 1899-09-19 | Alba L Holmes | Meter-box. |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| ATE175118T1 (de) | 1990-10-05 | 1999-01-15 | Medarex Inc | Gezielte immunostimulierung mit bispezifischen stoffen |
| ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| ES2096749T3 (es) | 1990-12-14 | 1997-03-16 | Cell Genesys Inc | Cadenas quimericas para vias de transduccion de señal asociada a un receptor. |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| JP3431140B2 (ja) | 1991-04-26 | 2003-07-28 | サーフィス・アクティブ・リミテッド | 抗体およびその使用方法 |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| DK0627940T3 (da) | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| DE69334258D1 (de) | 1992-08-21 | 2009-02-26 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| AU696293B2 (en) | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
| WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6465616B1 (en) | 1994-04-08 | 2002-10-15 | Bresagen Limited | Interleukin-5 antagonist |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| CN1117155C (zh) | 1994-07-29 | 2003-08-06 | 史密丝克莱恩比彻姆有限公司 | 新型化合物 |
| CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5677280A (en) | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
| EP0811691B1 (en) * | 1995-09-11 | 2004-12-01 | Kyowa Hakko Kogyo Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ES2172149T3 (es) | 1997-04-14 | 2002-09-16 | Micromet Ag | Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP2270147B2 (en) | 1999-04-09 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| US7033840B1 (en) * | 1999-11-09 | 2006-04-25 | Sri International | Reaction calorimeter and differential scanning calorimeter for the high-throughput synthesis, screening and characterization of combinatorial libraries |
| DK1233987T3 (da) | 1999-11-29 | 2009-09-28 | Bac Ip B V | Immobiliserede enkelt-domæne antigenbindende molekyler |
| US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
| WO2001060405A1 (fr) | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Inducteur de l'apoptose specifique a l'eosinophilie |
| AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| IL151348A0 (en) | 2000-04-13 | 2003-04-10 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| US20060257399A1 (en) | 2000-06-28 | 2006-11-16 | Glycofi, Inc. | Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform |
| KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
| US7632983B2 (en) | 2000-07-31 | 2009-12-15 | Biolex Therapeutics, Inc. | Expression of monoclonal antibodies in duckweed |
| CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002030954A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Procede de purification d'un anticorps |
| EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
| WO2003085119A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
| JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US20060147523A1 (en) * | 2002-10-16 | 2006-07-06 | Alan Fergusson | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JPWO2005035583A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | Ｉｌ−５受容体に特異的に結合する抗体組成物 |
| US20050226867A1 (en) | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
| US20050095602A1 (en) * | 2003-11-04 | 2005-05-05 | West Jason A. | Microfluidic integrated microarrays for biological detection |
| SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
| JP5047626B2 (ja) | 2003-12-10 | 2012-10-10 | メダレックス インコーポレイテッド | インターフェロンα抗体及びその使用 |
| US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| JP2008505174A (ja) * | 2004-07-15 | 2008-02-21 | ゼンコー・インコーポレイテッド | 最適化Ｆｃ変異体 |
| WO2006023403A2 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| ZA200701715B (en) | 2004-08-19 | 2008-07-30 | Genentech Inc | Polypeptide variants with altered effector function |
| JP2008525440A (ja) | 2004-12-23 | 2008-07-17 | グライコフィ， インコーポレイテッド | 主としてＧａｌＧｌｃＮＡｃＭａｎ５ＧＬｃＮＡｃ２グリコフォームを含む免疫グロブリン |
| WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
| AU2006299429B2 (en) * | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| ATE536373T1 (de) | 2005-10-21 | 2011-12-15 | Genzyme Corp | Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität |
| RU2519227C2 (ru) * | 2007-05-14 | 2014-06-10 | Медиммун, Ллк | Способы снижения числа эозинофилов |
-
2008
- 2008-05-14 RU RU2009146125/15A patent/RU2519227C2/ru active
- 2008-05-14 PL PL15190653T patent/PL3072525T3/pl unknown
- 2008-05-14 PT PT151906534T patent/PT3072525T/pt unknown
- 2008-05-14 CN CN201310170361.6A patent/CN103223167B/zh active Active
- 2008-05-14 KR KR1020167000810A patent/KR101827179B1/ko active IP Right Grant
- 2008-05-14 NO NO15190653A patent/NO3072525T3/no unknown
- 2008-05-14 EP EP08779619.9A patent/EP2068927B1/en active Active
- 2008-05-14 LT LTEP15190653.4T patent/LT3072525T/lt unknown
- 2008-05-14 CA CA2685222A patent/CA2685222C/en active Active
- 2008-05-14 DK DK08779619.9T patent/DK2068927T3/da active
- 2008-05-14 US US12/600,017 patent/US20100291073A1/en not_active Abandoned
- 2008-05-14 PT PT87796199T patent/PT2068927E/pt unknown
- 2008-05-14 HU HUE15190653A patent/HUE036885T2/hu unknown
- 2008-05-14 NZ NZ741494A patent/NZ741494A/en unknown
- 2008-05-14 MX MX2009012341A patent/MX2009012341A/es active IP Right Grant
- 2008-05-14 AU AU2008255027A patent/AU2008255027B2/en active Active
- 2008-05-14 DK DK15190653.4T patent/DK3072525T3/en active
- 2008-05-14 NZ NZ599278A patent/NZ599278A/en unknown
- 2008-05-14 CN CN2008800233678A patent/CN101848732B/zh active Active
- 2008-05-14 ES ES08779619.9T patent/ES2558689T3/es active Active
- 2008-05-14 KR KR1020097025886A patent/KR101588061B1/ko active IP Right Grant
- 2008-05-14 BR BRPI0811526A patent/BRPI0811526A2/pt not_active Application Discontinuation
- 2008-05-14 KR KR1020157023657A patent/KR20150107890A/ko not_active Application Discontinuation
- 2008-05-14 SI SI200831561A patent/SI2068927T1/sl unknown
- 2008-05-14 HU HUE08779619A patent/HUE026728T2/en unknown
- 2008-05-14 CA CA2986531A patent/CA2986531C/en active Active
- 2008-05-14 EP EP15190653.4A patent/EP3072525B1/en active Active
- 2008-05-14 MX MX2020011303A patent/MX2020011303A/es unknown
- 2008-05-14 SI SI200831949T patent/SI3072525T1/en unknown
- 2008-05-14 ES ES15190653.4T patent/ES2666165T3/es active Active
- 2008-05-14 WO PCT/US2008/006156 patent/WO2008143878A1/en active Application Filing
- 2008-05-14 PL PL08779619T patent/PL2068927T3/pl unknown
- 2008-05-14 JP JP2010508412A patent/JP2010527356A/ja active Pending
- 2008-05-14 SG SG10201503254TA patent/SG10201503254TA/en unknown
- 2008-05-14 SG SG10202000728UA patent/SG10202000728UA/en unknown
-
2009
- 2009-11-12 IL IL202102A patent/IL202102A/en active IP Right Grant
- 2009-11-12 HK HK09110575.3A patent/HK1132658A1/zh unknown
-
2011
- 2011-03-10 HK HK11102438.3A patent/HK1148220A1/xx unknown
- 2011-03-10 HK HK14100691.6A patent/HK1187542A1/xx unknown
- 2011-07-06 US US13/177,221 patent/US8501176B2/en active Active
-
2013
- 2013-07-03 US US13/934,271 patent/US9815895B2/en active Active
- 2013-12-20 AU AU2013273774A patent/AU2013273774B2/en active Active
-
2014
- 2014-02-14 RU RU2014105496A patent/RU2618455C2/ru active
-
2015
- 2015-07-27 IL IL240179A patent/IL240179B/en active IP Right Grant
- 2015-07-31 JP JP2015151502A patent/JP2016034940A/ja active Pending
- 2015-08-27 MX MX2015011174A patent/MX2015011174A/es active IP Right Grant
-
2016
- 2016-01-19 HR HRP20160058TT patent/HRP20160058T1/hr unknown
- 2016-01-20 CY CY20161100052T patent/CY1117594T1/el unknown
- 2016-12-12 AU AU2016273830A patent/AU2016273830B2/en active Active
-
2017
- 2017-07-12 JP JP2017135920A patent/JP2018021017A/ja active Pending
-
2018
- 2018-04-17 HR HRP20180611TT patent/HRP20180611T1/hr unknown
- 2018-04-27 CY CY20181100445T patent/CY1120417T1/el unknown
-
2019
- 2019-07-11 JP JP2019129029A patent/JP2019194242A/ja active Pending
-
2021
- 2021-10-21 JP JP2021172302A patent/JP2022023157A/ja active Pending
-
2023
- 2023-08-24 JP JP2023136193A patent/JP2023159349A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160058T1 (hr) | Postupci smanjenja razina eozinofila | |
| HRP20180753T1 (hr) | Antagonistička protutijela specifična za peptid koji je u vezi s genom za kalcitonin za liječenje cluster glavobolje | |
| HRP20191999T1 (hr) | Monoklonska protutijela anti-faktora xi i postupci njihove uporabe | |
| US11903997B2 (en) | Modulators of syndecan-2 and uses thereof | |
| US10370443B2 (en) | Method of treating autoimmune disease by administering antibodies to interleukin-6 | |
| JP2012046518A5 (hr) | ||
| HRP20190008T4 (hr) | Prevencija i liječenje sinukleinopatske i amiloidogene bolesti | |
| JP2020002172A5 (hr) | ||
| HRP20170687T1 (hr) | Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora | |
| JP2009531283A5 (hr) | ||
| JP2009518441A5 (hr) | ||
| HRP20221260T1 (hr) | Humanizirana i kimerna monoklonska protutijela za cd47 | |
| Hasan et al. | Repeated courses of rituximab in chronic ITP: three different regimens | |
| RU2010138612A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR | |
| JP2011522832A5 (hr) | ||
| JP2018535648A5 (hr) | ||
| CN106029693A (zh) | 抗il-13/il-17双特异性抗体及其用途 | |
| RU2014122189A (ru) | Способы снижения частоты и тяжести острых приступов астмы | |
| CA3115633A1 (en) | Combinations of anti-staphylococcus aureus antibodies | |
| WO2013024155A1 (en) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection | |
| Nakamura et al. | Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis | |
| JP2013525310A5 (hr) | ||
| JP2017520562A5 (hr) | ||
| CN116507365A (zh) | 抗ox40抗体在治疗肿瘤或癌症中的应用 | |
| Mildon et al. | Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma |